The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Phase II ALANIS trial: belantamab mafodotin combinations in newly diagnosed light-chain amyloidosis
Shaji Kumar, MD, Mayo Clinic, Rochester, MN, discusses the Phase II ALANIS study (NCT07224672) evaluating belantamab mafodotin in combination with bortezomib, cyclophosphamide and dexamethasone in newly diagnosed light-chain amyloidosis. He highlights the rationale for replacing daratumumab with the BCMA-targeted antibody-drug conjugate belantamab mafodotin, with the aim of achieving deeper and more durable responses and potentially faster organ responses. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
